[Clinical efficacy of paclitaxel combined with S-1 in the prevention and treatment of gastric cancer with peritoneal metastasis].
Peritoneal dissemination is the most common metastasis form in patients with highly advanced gastric cancer(AGC) or with recurrence after radical gastrectomy. The median survival time after manifestation of peritoneal carcinomatosis is about 4-6 months. Most systemic chemotherapeutic agents are not effective for peritoneal metastasis because of the blood-peritoneum barrier, although some adjuvant chemotherapy definitely improves overall survival. In this regard, neoadjuvant intraperitoneal-systemic chemotherapy(NIPS) has been recently considered as an additional adjuvant therapy for AGC with peritoneal metastasis. Combined chemotherapy of intravenous and intraperitoneal paclitaxel with oral S-1 has been confirmed by pharmacokinetic and pharmacodynamic studies to be well tolerated and well effective in gastric cancer patients with peritoneal metastasis. In this article, authors make a comprehensive introduction to clinical efficacy by adopting paclitaxel and S-1 to gastric cancer patients with peritoneal metastasis.
Department of Surgery, Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Digestive Surgery, Shanghai 200025, China. zzg1954@hotmail.com.
Zhenggang
Z
Zhu
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel